Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET)

J Ole Eriksen; M-B Jensen; A-V Laenkholm; T Kibøll; B Bruun Rasmussen; A S Knoop; S Ferree; T Haffner; W Buckingham; C Schaper; B Ejlertsen

doi:10.1158/1538-7445.SABCS15-P2-08-10

Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET)

J Ole Eriksen, M-B Jensen, A-V Laenkholm, T Kibøll, B Bruun Rasmussen, A S Knoop, S Ferree, T Haffner, W Buckingham, C Schaper, B Ejlertsen

Institut for Klinisk Medicin

Originalsprog	Engelsk
Artikelnummer	P2-08-10
Tidsskrift	Cancer Research
Vol/bind	76
Udgave nummer	4 Supplement
Antal sider	1
ISSN	0008-5472
DOI	https://doi.org/10.1158/1538-7445.SABCS15-P2-08-10
Status	Udgivet - 2016

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1158/1538-7445.SABCS15-P2-08-10

Citationsformater

Eriksen, J. O., Jensen, M.-B., Laenkholm, A.-V., Kibøll, T., Rasmussen, B. B., Knoop, A. S., Ferree, S., Haffner, T., Buckingham, W., Schaper, C., & Ejlertsen, B. (2016). Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET). Cancer Research, 76(4 Supplement), Artikel P2-08-10. https://doi.org/10.1158/1538-7445.SABCS15-P2-08-10

Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET). / Eriksen, J Ole; Jensen, M-B; Laenkholm, A-V et al.
I: Cancer Research, Bind 76, Nr. 4 Supplement, P2-08-10, 2016.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Eriksen, JO, Jensen, M-B, Laenkholm, A-V, Kibøll, T, Rasmussen, BB, Knoop, AS, Ferree, S, Haffner, T, Buckingham, W, Schaper, C & Ejlertsen, B 2016, 'Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET)', Cancer Research, bind 76, nr. 4 Supplement, P2-08-10. https://doi.org/10.1158/1538-7445.SABCS15-P2-08-10

Eriksen JO, Jensen MB, Laenkholm AV, Kibøll T, Rasmussen BB, Knoop AS et al. Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET). Cancer Research. 2016;76(4 Supplement):P2-08-10. doi: 10.1158/1538-7445.SABCS15-P2-08-10

@article{82310531414842db9aded78e2aba59ae,

title = "Validation of prediction of local recurrence (LR) by Prosigna{\textregistered} (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET)",

author = "Eriksen, {J Ole} and M-B Jensen and A-V Laenkholm and T Kib{\o}ll and Rasmussen, {B Bruun} and Knoop, {A S} and S Ferree and T Haffner and W Buckingham and C Schaper and B Ejlertsen",

year = "2016",

doi = "10.1158/1538-7445.SABCS15-P2-08-10",

language = "English",

volume = "76",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research",

number = "4 Supplement",

}

TY - ABST

T1 - Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET)

AU - Eriksen, J Ole

AU - Jensen, M-B

AU - Laenkholm, A-V

AU - Kibøll, T

AU - Rasmussen, B Bruun

AU - Knoop, A S

AU - Ferree, S

AU - Haffner, T

AU - Buckingham, W

AU - Schaper, C

AU - Ejlertsen, B

PY - 2016

Y1 - 2016

U2 - 10.1158/1538-7445.SABCS15-P2-08-10

DO - 10.1158/1538-7445.SABCS15-P2-08-10

M3 - Conference abstract in journal

SN - 0008-5472

VL - 76

JO - Cancer Research

JF - Cancer Research

IS - 4 Supplement

M1 - P2-08-10

ER -